M4K3233
M4K3233 is a selective ALK2 PROTAC degrader with a pDC50 of 7.3 and a pIC50 of 6.6. M4K3233 recruits CRBN to form a ternary complex with ALK2, mediating ALK2 degradation via the proteasomal and lysosomal pathways. M4K3233 induces moderate downregulation of RIPK2 and significant downregulation of SIK3 in mammalian cells. M4K3233 is applicable to research related to glioblastoma.
(Pink: ALK2 ligand (HY-149591); Blue: Cereblon ligand (HY-14658); Black: linker).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C44H48N6O7
- Masse moléculaire:772.89
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
M4K3233 (1 μM; 24 h) is a selective ALK2 degrader in ALK2-overexpressing HEK-293 cells and U87-MG glioblastoma cells, significantly reducing ALK2 levels alongside a small set of off-target proteins including PDE6D, FIZ1, SIK3, and RIPK2, while sparing most other kinases[1].
M4K3233 (serial dilutions; 4 h) promotes ternary complex formation between ALK2 and CRBN in HEK-293 cells with an apparent pEC50 of 7.42, as measured by a NanoBRET PPI assay[1].
M4K3233 (0.0002-30 μM; 8 days) inhibits proliferation of patient-derived PDHGG cell lines with GI50 values from 0.3 μM to 5 μM, but this effect appears independent of CRBN-mediated ALK2 degradation[1].
M4K3233 (0.0002-30 μM; 4 days) reduces viability of U87-MG glioblastoma cells, but this cytotoxic effect is independent of CRBN-mediated ALK2 degradation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ALK2-HiBiT transfected HEK-293 cells
-
Concentration:1 μM (M4K3233, 24 h incubation); 20 μM pomalidomide (20 min pretreatment); 20 μM M4K2009 (20 min pretreatment); 1 μM MG132 (20 min pretreatment); 1 μM bafilomycin A1 (20 min pretreatment)
-
Incubation Time:24 h (M4K3233 treatment); 20 min (pretreatments)
-
Result:Blocked ALK2 degradation when cells were pretreated with either pomalidomide or M4K2009, confirming reliance on both ALK2 and CRBN binding.
Partially recovered ALK2 levels when cells were pretreated with either MG132 or bafilomycin A1, while combined pretreatment with both inhibitors completely blocked ALK2 degradation.
Chemical Information
-
Masse moléculaire 772.89
-
Formule C44H48N6O7
-
SMILES
CC1=C(C2=CC=C(N3CCN(CC4CCN(C5=CC=C(C(N(C6CCC(NC6=O)=O)C7=O)=O)C7=C5)CC4)CC3)C=C2)C=NC=C1C8=CC(OC)=C(OC)C(OC)=C8
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
M4K3233 Related Classifications
HY-183717 Related Classifications
Powered by Bioz